HC Wainwright Has Negative Forecast for COLL Q2 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a report released on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the specialty pharmaceutical company will post earnings per share of $1.48 for the quarter, down from their previous estimate of $1.65. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $6.34 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2026 earnings at $2.14 EPS and FY2026 earnings at $6.27 EPS.

A number of other brokerages also recently issued reports on COLL. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Barclays dropped their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.40.

Collegium Pharmaceutical Trading Up 0.7%

Shares of COLL opened at $32.50 on Friday. The business has a 50-day moving average of $36.81 and a 200 day moving average of $41.40. Collegium Pharmaceutical has a fifty-two week low of $26.16 and a fifty-two week high of $50.79. The firm has a market cap of $1.05 billion, a P/E ratio of 19.01 and a beta of 0.77. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. During the same period last year, the business posted $1.77 EPS. The company’s revenue was up 12.9% compared to the same quarter last year.

Insider Buying and Selling

In related news, EVP David Dieter sold 13,976 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares of the company’s stock, valued at $2,900,225.70. The trade was a 41.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.85% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of the company. James Investment Research Inc. lifted its position in Collegium Pharmaceutical by 19.7% in the first quarter. James Investment Research Inc. now owns 7,110 shares of the specialty pharmaceutical company’s stock valued at $235,000 after purchasing an additional 1,170 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in Collegium Pharmaceutical in the first quarter valued at approximately $3,185,000. Louisiana State Employees Retirement System bought a new stake in Collegium Pharmaceutical in the first quarter valued at approximately $463,000. Ritholtz Wealth Management lifted its position in Collegium Pharmaceutical by 35.1% in the first quarter. Ritholtz Wealth Management now owns 8,283 shares of the specialty pharmaceutical company’s stock valued at $274,000 after purchasing an additional 2,150 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in Collegium Pharmaceutical by 284.4% in the first quarter. SG Americas Securities LLC now owns 66,397 shares of the specialty pharmaceutical company’s stock valued at $2,196,000 after purchasing an additional 49,123 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.